Mutation analysis of CBP and PCAF reveals rare inactivating mutations in cancer cell lines but not in primary tumours

H Ozdağ; S J Batley; A Försti; N G Iyer; Y Daigo; J Boutell; M J Arends; B A J Ponder; T Kouzarides; C Caldas

doi:10.1038/sj.bjc.6600554

Mutation analysis of CBP and PCAF reveals rare inactivating mutations in cancer cell lines but not in primary tumours

Br J Cancer. 2002 Nov 4;87(10):1162-5. doi: 10.1038/sj.bjc.6600554.

Authors

H Ozdağ¹, S J Batley, A Försti, N G Iyer, Y Daigo, J Boutell, M J Arends, B A J Ponder, T Kouzarides, C Caldas

Affiliation

¹ Cancer Genomics Program, Department of Oncology, University of Cambridge, Hutchison/MRC Research Centre, Cambridge CB2 2XZ, UK.

Abstract

In this study we screened the histone acetyltransferases CBP and PCAF for mutations in human epithelial cancer cell lines and primary tumours. We identified two CBP truncations (both in cell lines), seven PCAF missense variants and four CBP intronic microdeletions. These data suggest that neither gene is commonly inactivated in human epithelial cancers.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Acetyltransferases / genetics*
Blotting, Western
CREB-Binding Protein
Cell Cycle Proteins / genetics
Exons
Histone Acetyltransferases
Humans
Introns
Mutation*
Neoplasms, Glandular and Epithelial / genetics*
Nuclear Proteins / genetics*
Saccharomyces cerevisiae Proteins / genetics*
Trans-Activators / genetics*
Transcription Factors
Tumor Cells, Cultured
p300-CBP Transcription Factors

Substances

Cell Cycle Proteins
Nuclear Proteins
Saccharomyces cerevisiae Proteins
Trans-Activators
Transcription Factors
Acetyltransferases
CREB-Binding Protein
CREBBP protein, human
Histone Acetyltransferases
p300-CBP Transcription Factors
p300-CBP-associated factor